Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
| Title: | Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. |
|---|---|
| Authors: | Ferdinands, Jill M.1 zdn5@cdc.gov, Rao, Suchitra2, Dixon, Brian E.3,4, Mitchell, Patrick K.5, DeSilva, Malini B.6, Irving, Stephanie A.7, Lewis, Ned8, Natarajan, Karthik9,10, Stenehjem, Edward11, Grannis, Shaun J.3,12, Jungmi Han9, McEvoy, Charlene6, Ong, Toan C.2, Naleway, Allison L.7, Reese, Sarah E.5, Embi, Peter J.3,12,13, Dascomb, Kristin11, Klein, Nicola P.8, Griggs, Eric P.1, Konatham, Deepika14 |
| Source: | MMWR: Morbidity & Mortality Weekly Report. 2/18/2022, Vol. 71 Issue 7, p255-263. 9p. |
| Subject Terms: | *SARS-CoV-2 Omicron variant, *SARS-CoV-2 Delta variant, *OUTPATIENT medical care, *VACCINE effectiveness, *BOOSTER vaccines |
| Company/Entity: | CENTERS for Disease Control & Prevention (U.S.) |
| Abstract: | CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons receive a third primary dose.* Waning of vaccine protection after 2 doses of mRNA vaccine has been observed during the period of the SARS-CoV-2 B.1.617.2 (Delta) variant predominance† (1-5), but little is known about durability of protection after 3 doses during periods of Delta or SARS-CoV-2 B.1.1.529 (Omicron) variant predominance. A test-negative case-control study design using data from eight VISION Network sites§ examined vaccine effectiveness (VE) against COVID-19 emergency department/urgent care (ED/UC) visits and hospitalizations among U.S. adults aged ≥18 years at various time points after receipt of a second or third vaccine dose during two periods: Delta variant predominance and Omicron variant predominance (i.e., periods when each variant accounted for ≥50% of sequenced isolates).¶ Persons categorized as having received 3 doses included those who received a third dose in a primary series or a booster dose after a 2 dose primary series (including the reduced-dosage Moderna booster). The VISION Network analyzed 241,204 ED/UC encounters** and 93,408 hospitalizations across 10 states during August 26, 2021-January 22, 2022. VE after receipt of both 2 and 3 doses was lower during the Omicron-predominant than during the Delta-predominant period at all time points evaluated. During both periods, VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination. During the Omicron period, VE against ED/UC visits was 87% during the first 2 months after a third dose and decreased to 66% among those vaccinated 4-5 months earlier; VE against hospitalizations was 91% during the first 2 months following a third dose and decreased to 78% ≥4 months after a third dose. For both Delta- and Omicron-predominant periods, VE was generally higher for protection against hospitalizations than against ED/UC visits. All eligible persons should remain up to date with recommended COVID-19 vaccinations to best protect against COVID-19-associated hospitalizations and ED/UC visits. [ABSTRACT FROM AUTHOR] |
| Copyright of MMWR: Morbidity & Mortality Weekly Report is the property of Centers for Disease Control & Prevention (CDC) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Academic Search Complete |
| FullText | Links: – Type: pdflink Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=01492195&ISBN=&volume=71&issue=7&date=20220218&spage=255&pages=255-263&title=MMWR: Morbidity & Mortality Weekly Report&atitle=Waning%202-Dose%20and%203-Dose%20Effectiveness%20of%20mRNA%20Vaccines%20Against%20COVID-19-Associated%20Emergency%20Department%20and%20Urgent%20Care%20Encounters%20and%20Hospitalizations%20Among%20Adults%20During%20Periods%20of%20Delta%20and%20Omicron%20Variant%20Predominance%20-%20VISION%20Network%2C%2010%20States%2C%20August%202021-January%202022.&aulast=Ferdinands%2C%20Jill%20M.&id=DOI:10.15585/mmwr.mm7107e2 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: a9h DbLabel: Academic Search Complete An: 155302043 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Ferdinands%2C+Jill+M%2E%22">Ferdinands, Jill M.</searchLink><relatesTo>1</relatesTo><i> zdn5@cdc.gov</i><br /><searchLink fieldCode="AR" term="%22Rao%2C+Suchitra%22">Rao, Suchitra</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Dixon%2C+Brian+E%2E%22">Dixon, Brian E.</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Mitchell%2C+Patrick+K%2E%22">Mitchell, Patrick K.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22DeSilva%2C+Malini+B%2E%22">DeSilva, Malini B.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Irving%2C+Stephanie+A%2E%22">Irving, Stephanie A.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Lewis%2C+Ned%22">Lewis, Ned</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Natarajan%2C+Karthik%22">Natarajan, Karthik</searchLink><relatesTo>9,10</relatesTo><br /><searchLink fieldCode="AR" term="%22Stenehjem%2C+Edward%22">Stenehjem, Edward</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Grannis%2C+Shaun+J%2E%22">Grannis, Shaun J.</searchLink><relatesTo>3,12</relatesTo><br /><searchLink fieldCode="AR" term="%22Jungmi+Han%22">Jungmi Han</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22McEvoy%2C+Charlene%22">McEvoy, Charlene</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Ong%2C+Toan+C%2E%22">Ong, Toan C.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Naleway%2C+Allison+L%2E%22">Naleway, Allison L.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Reese%2C+Sarah+E%2E%22">Reese, Sarah E.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Embi%2C+Peter+J%2E%22">Embi, Peter J.</searchLink><relatesTo>3,12,13</relatesTo><br /><searchLink fieldCode="AR" term="%22Dascomb%2C+Kristin%22">Dascomb, Kristin</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Klein%2C+Nicola+P%2E%22">Klein, Nicola P.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Griggs%2C+Eric+P%2E%22">Griggs, Eric P.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Konatham%2C+Deepika%22">Konatham, Deepika</searchLink><relatesTo>14</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22MMWR%3A+Morbidity+%26+Mortality+Weekly+Report%22">MMWR: Morbidity & Mortality Weekly Report</searchLink>. 2/18/2022, Vol. 71 Issue 7, p255-263. 9p. – Name: Subject Label: Subject Terms Group: Su Data: *<searchLink fieldCode="DE" term="%22SARS-CoV-2+Omicron+variant%22">SARS-CoV-2 Omicron variant</searchLink><br />*<searchLink fieldCode="DE" term="%22SARS-CoV-2+Delta+variant%22">SARS-CoV-2 Delta variant</searchLink><br />*<searchLink fieldCode="DE" term="%22OUTPATIENT+medical+care%22">OUTPATIENT medical care</searchLink><br />*<searchLink fieldCode="DE" term="%22VACCINE+effectiveness%22">VACCINE effectiveness</searchLink><br />*<searchLink fieldCode="DE" term="%22BOOSTER+vaccines%22">BOOSTER vaccines</searchLink> – Name: SubjectCompany Label: Company/Entity Group: Su Data: <searchLink fieldCode="DE" term="%22CENTERS+for+Disease+Control+%26+Prevention+%28U%2ES%2E%29%22">CENTERS for Disease Control & Prevention (U.S.)</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons receive a third primary dose.* Waning of vaccine protection after 2 doses of mRNA vaccine has been observed during the period of the SARS-CoV-2 B.1.617.2 (Delta) variant predominance† (1-5), but little is known about durability of protection after 3 doses during periods of Delta or SARS-CoV-2 B.1.1.529 (Omicron) variant predominance. A test-negative case-control study design using data from eight VISION Network sites§ examined vaccine effectiveness (VE) against COVID-19 emergency department/urgent care (ED/UC) visits and hospitalizations among U.S. adults aged ≥18 years at various time points after receipt of a second or third vaccine dose during two periods: Delta variant predominance and Omicron variant predominance (i.e., periods when each variant accounted for ≥50% of sequenced isolates).¶ Persons categorized as having received 3 doses included those who received a third dose in a primary series or a booster dose after a 2 dose primary series (including the reduced-dosage Moderna booster). The VISION Network analyzed 241,204 ED/UC encounters** and 93,408 hospitalizations across 10 states during August 26, 2021-January 22, 2022. VE after receipt of both 2 and 3 doses was lower during the Omicron-predominant than during the Delta-predominant period at all time points evaluated. During both periods, VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination. During the Omicron period, VE against ED/UC visits was 87% during the first 2 months after a third dose and decreased to 66% among those vaccinated 4-5 months earlier; VE against hospitalizations was 91% during the first 2 months following a third dose and decreased to 78% ≥4 months after a third dose. For both Delta- and Omicron-predominant periods, VE was generally higher for protection against hospitalizations than against ED/UC visits. All eligible persons should remain up to date with recommended COVID-19 vaccinations to best protect against COVID-19-associated hospitalizations and ED/UC visits. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of MMWR: Morbidity & Mortality Weekly Report is the property of Centers for Disease Control & Prevention (CDC) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=155302043 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.15585/mmwr.mm7107e2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 255 Subjects: – SubjectFull: CENTERS for Disease Control & Prevention (U.S.) Type: general – SubjectFull: SARS-CoV-2 Omicron variant Type: general – SubjectFull: SARS-CoV-2 Delta variant Type: general – SubjectFull: OUTPATIENT medical care Type: general – SubjectFull: VACCINE effectiveness Type: general – SubjectFull: BOOSTER vaccines Type: general Titles: – TitleFull: Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ferdinands, Jill M. – PersonEntity: Name: NameFull: Rao, Suchitra – PersonEntity: Name: NameFull: Dixon, Brian E. – PersonEntity: Name: NameFull: Mitchell, Patrick K. – PersonEntity: Name: NameFull: DeSilva, Malini B. – PersonEntity: Name: NameFull: Irving, Stephanie A. – PersonEntity: Name: NameFull: Lewis, Ned – PersonEntity: Name: NameFull: Natarajan, Karthik – PersonEntity: Name: NameFull: Stenehjem, Edward – PersonEntity: Name: NameFull: Grannis, Shaun J. – PersonEntity: Name: NameFull: Jungmi Han – PersonEntity: Name: NameFull: McEvoy, Charlene – PersonEntity: Name: NameFull: Ong, Toan C. – PersonEntity: Name: NameFull: Naleway, Allison L. – PersonEntity: Name: NameFull: Reese, Sarah E. – PersonEntity: Name: NameFull: Embi, Peter J. – PersonEntity: Name: NameFull: Dascomb, Kristin – PersonEntity: Name: NameFull: Klein, Nicola P. – PersonEntity: Name: NameFull: Griggs, Eric P. – PersonEntity: Name: NameFull: Konatham, Deepika IsPartOfRelationships: – BibEntity: Dates: – D: 18 M: 02 Text: 2/18/2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 01492195 Numbering: – Type: volume Value: 71 – Type: issue Value: 7 Titles: – TitleFull: MMWR: Morbidity & Mortality Weekly Report Type: main |
| ResultId | 1 |